Treatments of HCC with PVTT extended to the main portal vein are multidisciplinary and include surgery, intervention such as trans-arterial chemoembolization (TACE), radiotherapy, tyrosine kinase inhibitors (TKIs), and programmed cell death protein 1 inhibitors (PD-1) (7, 8). Here, PDCD1 is linked to hepatocellular carcinoma.